It is with great pleasure that we present to you the third 2011 quarterly issue of the Jerusalem Life Science Bulletin, highlighting the latest achievements and news of Jerusalem’s life science cluster.
In July, we had the pleasure of hosting a delegation from San Antonio, led by Mayor Julián Castro and including Ann Stevens, President of Biomed SA, San Antonio’s biomed initiative. As America‘s seventh largest city, San Antonio is a regional hub for medical care and one of the nation’s bioscience leaders in key disease areas including diabetes, military and regenerative medicine, the neurosciences, cancer, and infectious diseases, among others. A collaboration agreement was signed between Biomed SA, and Biojerusalem and we are currently working on the its implementation to bring about our vision of mutual benefit to both regions.
In September BioJerusalem took part in an Entrepreneurship Symposium organized by Bioabroad. The Symposium took place in three major U.S life sciences hubs; Boston, Washington D.C. and San Francisco. The purpose of the Symposium was to meet with entrepreneurs who are interested in establishing their businesses in Israel and to provide them with all of the relevant information. Alongside BioJerusalem, the panel of experts included representatives from the Ministry of Industry, Trade and Labor, the Ministry of Immigration Absorption, and Tax and Legal experts.
The Jerusalem Biomed sector was chosen as the focus of The Jerusalem Economic Forum hosted by Jerusalem Mayor, Nir Barkat. The forum convenes several times per year, focusing each time on a topic of relevance to the city’s economic development. I would like to thank our panel members, Dr. Aharon Schwartz, Prof. Shlomo Mor-Yosef and Prof. Ariel Darvasi, for a very interesting panel discussion.
With best wishes,
|Clinical & Regulatory News|
BioLineRx Announces First Subject Enrolled in Phase I Clinical Trial of BL-1021 for Neuropathic Pain The primary endpoints of the study are to examine the safety and tolerability of a single administration or multiple administrations of BL-1021
Intec Pharma jumps on positive Parkinson’s results The company’s Levodopa accordion pill was found to greatly improve current versions of the drug
BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain Results show the drug is safe and well tolerated
|Scientific/Medical Discoveries & Breakthroughs|
Yissum Introduces Novel Markers for Brain Cancer Survival Prognosis and a New Treatment Method for the Disease Findings were published in the prestigious Cancer Research journal
Path to cure for diabetes opens Glucose-sensing enzyme holds the key to insulin production
|Collaborations & Alliances|
BioMed SA strikes deal with BioJerusalem San Antonio mayor, BioMed SA president co-sign memorandum of intent with Jerusalem Development Authority initiative to begin building relationships to benefit biomedical sectors of both regions
Hebrew University’s Yissum teams with Shaare Zedek Hospital Yissum CEO Yaacov Michlin: We’ll be the only commercialization company in Israel that works for both a university and a hospital
BioMarCare Technologies Ltd. Receives a $900k Grant for a Joint Project with Ariadne Inc. BioMarCare and Ariadne Inc. will jointly develop a diagnostic test
BioLineRx In-Licenses BL-7050 A Novel, Orally-Available Molecule for the Treatment of Neuropathic and Inflammatory Pain
Hadasit launches Jewish-Arab biomed incubator in Galilee Hadasit has pledged to invest NIS 7.5 million in Ways over the next five years
“Large drug companies are stuck in a rut” Teva’s new VC fund head Dr. Aharon Schwartz tells “Globes” about changing trends in drug development
BioLineRx Announces Plans to Launch ADR Program on NASDAQ BioLineRx to list shares through American Depositary Receipts
BioLineRx ADRs Issues Begin Trading on NASDAQ
Chief Scientist approves NIS 5.9m Biocancell pancreatic cancer trial The FDA has approved a Phase IIb clinical trial (multicenter efficacy trial) of the BC-819 drug for the treatment of pancreatic cancer
Intec Pharma raises NIS 10.8m in rights issue The company, which develops improved versions of current drugs, received orders for 99.96% of the units offered